KR20220015451A - 흉선 재생과 t 세포의 재구성을 위한 조성물 및 방법 - Google Patents

흉선 재생과 t 세포의 재구성을 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20220015451A
KR20220015451A KR1020217042865A KR20217042865A KR20220015451A KR 20220015451 A KR20220015451 A KR 20220015451A KR 1020217042865 A KR1020217042865 A KR 1020217042865A KR 20217042865 A KR20217042865 A KR 20217042865A KR 20220015451 A KR20220015451 A KR 20220015451A
Authority
KR
South Korea
Prior art keywords
cells
ntec
e4orf1
thymic
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217042865A
Other languages
English (en)
Korean (ko)
Inventor
폴 윌리암 피네건
다니엘 조지프 놀란
카롤리나 쿠차로바
마이클 다니엘 긴즈버그
케니스 엔. 윌스
Original Assignee
앤지오크린 바이오사이언스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 앤지오크린 바이오사이언스 인코포레이티드 filed Critical 앤지오크린 바이오사이언스 인코포레이티드
Publication of KR20220015451A publication Critical patent/KR20220015451A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Vascular Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020217042865A 2019-05-28 2020-05-28 흉선 재생과 t 세포의 재구성을 위한 조성물 및 방법 Ceased KR20220015451A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962853452P 2019-05-28 2019-05-28
US62/853,452 2019-05-28
PCT/US2020/034932 WO2020243310A1 (en) 2019-05-28 2020-05-28 Compositions and methods for thymic regeneration and t-cell reconstitution

Publications (1)

Publication Number Publication Date
KR20220015451A true KR20220015451A (ko) 2022-02-08

Family

ID=73553922

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217042865A Ceased KR20220015451A (ko) 2019-05-28 2020-05-28 흉선 재생과 t 세포의 재구성을 위한 조성물 및 방법

Country Status (10)

Country Link
US (1) US20220226391A1 (https=)
EP (1) EP3976065A4 (https=)
JP (1) JP7637418B2 (https=)
KR (1) KR20220015451A (https=)
CN (1) CN114340642A (https=)
AU (1) AU2020283586A1 (https=)
CA (1) CA3141989A1 (https=)
IL (1) IL288439A (https=)
SG (1) SG11202113119QA (https=)
WO (1) WO2020243310A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2753441C2 (ru) 2016-09-13 2021-08-16 Ангиокрин Биосайенс, Инк. Гематоэнцефалический барьер, содержащий сконструированные эндотелиальные клетки
WO2024155791A1 (en) * 2023-01-18 2024-07-25 Angiocrine Bioscience, Inc. Use of umbilical vein endothelial cells for the treatment of lung injury
WO2025245461A1 (en) * 2024-05-23 2025-11-27 Thymofox Inc. Methods of activating foxn1

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8465732B2 (en) * 2007-01-19 2013-06-18 Cornell Research Foundation, Inc. Endothelial cells expressing adenovirus E4ORF1 and methods of use thereof
WO2016069911A1 (en) * 2014-10-29 2016-05-06 Jarrod Dudakov Use of bmp4 for thymic regeneration
RU2743761C2 (ru) 2014-12-19 2021-02-25 Анджиокрин Биосайенс, Инк. Биосовместимые имплантаты, содержащие сконструированные эндотелиальные клетки
RU2753441C2 (ru) * 2016-09-13 2021-08-16 Ангиокрин Биосайенс, Инк. Гематоэнцефалический барьер, содержащий сконструированные эндотелиальные клетки

Also Published As

Publication number Publication date
EP3976065A1 (en) 2022-04-06
JP7637418B2 (ja) 2025-02-28
US20220226391A1 (en) 2022-07-21
IL288439A (en) 2022-01-01
AU2020283586A1 (en) 2021-12-23
CA3141989A1 (en) 2020-12-03
JP2022534586A (ja) 2022-08-02
SG11202113119QA (en) 2021-12-30
CN114340642A (zh) 2022-04-12
WO2020243310A1 (en) 2020-12-03
EP3976065A4 (en) 2023-05-03

Similar Documents

Publication Publication Date Title
Ghosh et al. T-cell gene therapy for perforin deficiency corrects cytotoxicity defects and prevents hemophagocytic lymphohistiocytosis manifestations
Swan et al. IL7 and IL7 Flt3L co-expressing CAR T cells improve therapeutic efficacy in mouse EGFRvIII heterogeneous glioblastoma
CN106659742A (zh) 表达免疫应答刺激细胞因子以吸引和/或激活免疫细胞的基因修饰间充质干细胞
TW201736594A (zh) 抗原特異性ｔｃｒ的新生成
US9228007B1 (en) Recombinant human progenitor cells, engineered human thymocytes, and engineered human T cells
KR20220015451A (ko) 흉선 재생과 t 세포의 재구성을 위한 조성물 및 방법
EA010434B1 (ru) Способ получения цитотоксических лимфоцитов
US9592259B2 (en) APC-mediated tolerance induction for therapy of multiple sclerosis
US11186827B1 (en) Genetically modified stem cells
Jung et al. Stimulatory effect of HGF‐overexpressing adipose tissue‐derived mesenchymal stem cells on thymus regeneration in a rat thymus involution model
KR20210015873A (ko) 천연 킬러 세포를 제조하는 방법 및 이의 용도
Mateus-Tique et al. Armored macrophage-targeted CAR-T cells reset and reprogram the tumor microenvironment and control metastatic cancer growth
JP2007523640A (ja) 免疫応答を誘導または調節する方法
CA2636876A1 (en) Methods and kits for expanding hematopoietic stem cells
EP4308132A1 (en) Human macrophages resistant to tumor-induced repolarization
CA2548157A1 (en) Cell culture with nm23, cell culture media comprising nm23 and therapeutic use of cells cultured in the presence of nm23.
Nayak et al. Modulation of renal carcinoma cells in vitro: Comparison after transduction with retroviral vector containing a human IFN-gamma gene versus incubation with soluble IFN-gamma
US20250270511A1 (en) Genetically engineered cells, their uses, and methods of making same
US20230414720A1 (en) Use of insulin-like growth factors with gamma-chain cytokines to induce homeostatic proliferation of lymphocytes
EP4134086A1 (en) Human macrophages resistant to tumor-induced repolarization
EP3672605B1 (en) In utero transplantation of factor viii-expressing cells for treatment of hemophilia
WO2023244737A1 (en) Improved enhancers and vectors
WO2023122099A2 (en) Crispr-based gene editing to preserve splicing and expression of foxp3 isoforms 1 and 2
KR20230042525A (ko) 냉동보존된 내피 세포 조성물
by Chimeric et al. GENE THERAPY OR THE NERVOUS SYSTEM I

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601